Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 17

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 of common stock on exercise of stock options and vesting of restricted stock units689 — 11,281 — — 11,281 Issuance of common stock under ESPP58 — 1,190 — — 1,190 Tax portion of vested restricted stock units— — (2,182)— — (2,182)Stock-based compensation expense (employee)— — 8,335 — — 8,335 Stock-based compensation expense (ESPP)— — 412 — — 412 Net income— — — 15,155 — 15,155 Currency translation adjustments— — — — 9,328 9,328 Balance at September 30, 202477,491 $77 $1,646,343 $(449,096)$(21,282)$1,176,042 Balance at December 31, 202373,265 $73 $1,536,168 $(468,121)$(24,018)$1,044,102 Issuance of common stock and options for acquisition2,698 3 74,142 — — 74,145 Issuance of common stock upon exercise of stock options and vesting of restricted stock units1,390 1 13,842 — — 13,843 Issuance of common stock under ESPP138 — 2,886 — — 2,886 Tax portion of vested restricted stock units— — (7,315)— — (7,315)Stock-based compensation expense (employee)— — 25,636 — — 25,636 Stock-based compensation expense (ESPP)— — 984 — — 984 Net income— — — 19,025 — 19,025 Currency translation adjustments— — — — 2,736 2,736 Balance at September 30, 202477,491 $77 $1,646,343 $(449,096)$(21,282)$1,176,042 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

VERACYTE, INC.  

Condensed Consolidated Statements of Cash Flows 

(Unaudited) 

(In thousands)

 Nine Months